Columbia Labs
This article was originally published in The Tan Sheet
Executive Summary
Firm expands sales force to 135 people and is deploying group to detail its women's healthcare products. Offerings include Advantage-S spermicidal contraceptive and RepHresh Vaginal Gel marketed to OB/GYNs and other professional audiences, President & CEO Fred Wilkinson announces in Aug. 7 earnings call. The OTC products' Q2 sales helped boost Columbia's net revenues 36% to $4.9 mil. over Q1. Wilkinson predicts increased sales efforts behind Columbia's present products and launch of Rx Striant testosterone buccal system - which FDA approved June 19 - will allow the company to garner earnings, cash positive numbers by year end. Columbia posted a $4.4 mil. net loss in the second quarter...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.